Trump’s executive order to cap U.S. costs risks limiting the supply of new pharmaceuticals. President Donald Trump’s ...

Ken Hall takes a closer look at GSK after the FTSE 100 pharmaceutical giant's positive first quarter earnings update.

It’s also worth noting that ... its impact on Indian pharmaceutical companies is likely to be uneven. Generic-focused players will not be affected much and may even benefit from a more level ...

Government signs deal to see huge investment in mRNA vaccine manufacturing which could help tackle the next pandemic and ...

Today we hear from Jeremy Spivey about clinical trial outsourcing, and whether pharma companies should be looking ... of the trial process is in no way worth delays in product approval that ...

UnitedHealth Group faces real PBM reform risks, but legal paths, financials, and market pricing suggest opportunity in ...

Squeezed by insurers and middlemen, independent pharmacists such as Mr Jolley find themselves on the front lines of a tariff storm. Nearly everyone down the line — drugmakers, pharmacies, wholesalers, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

To thrive in this environment, pharma ... worth of digital transformation in the space of just a few months – but while the industry has embraced digital tools and techniques, most companies ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high costs paid by U.S. patients.

An Enquirer analysis found that doctors, nurses and other practitioners received $136 million from pharma and biotech ...